In this issue
mAbs
Volume 4, Issue 1January/February 2012
View current issue
About the cover
Modeling of a triplebody. Graphical representation of a triplebody geometry as a ribbon model. ScFvs are orientated in the direction front to back, HLA-DR...Continue reading
Most Popular Downloads
Janice M. Reichert
Eugen Dhimolea and Janice M. Reichert
Upcoming Meetings
Editor-in-Chief
Janice M. Reichert, Ph.D.
Online ISSN: 1942-0870 DOI: 10.4161/mabs
Medline/PubMed, PubMed Central, Science Citation Index Expanded, Biotechnology Citation Index, Biological Abstracts, Biosis Previews, Scopus
Email the Managing Editor, Neil Kahn.
Important Journal Links
Submit your manuscript to mAbs
Recommend mAbs to your library
mAbs 101 - What are mAbs?
See this section for a comprehensive and up-to-date table with FDA-approved therapeutic mAbs.
New feature! 'Like' mAbs on Facebook!
'Like' mAbs on Facebook to find out about newly added PDFs to forthcoming issues.
About the Journal
In January of 2009 we launched mAbs, an international peer-reviewed journal focused exclusively on antibodies.
Our mission is to provide a forum for communication on all topics relevant to antibody research and development, with a focus on therapeutics. In the last decade, there has been a rapid increase in antibody research and development performed by academia, government and industry located world wide. Novel antibody therapeutics are entering clinical study by commercial sponsors at an average rate of 50 per year that is predicted to continue well into the future. Over 30 mAb therapeutics have been approved and global sales of these products are approximately $40 billion. Our broad scope ensures that the journal's articles are of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community including readers concerned with technology transfer, legal issues, investment, regulatory requirements and strategic planning.
